Log In
Print
BCIQ
Print
Print this Print this
 

patiromer (RLY5016)

  Manage Alerts
Collapse Summary General Information
Company Relypsa Inc.
DescriptionHigh-capacity oral potassium binder
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationHyperkalemia
Indication DetailsTreat hyperkalemia; Treat hyperkalemia in chronic kidney disease (CKD) patients; Treat hyperkalemia in patients with nephropathy due to Type II diabetes and chronic kidney disease (CKD)
Regulatory Designation

U.S. - Special Protocol Assessment (Treat hyperkalemia in chronic kidney disease (CKD) patients)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today